We are an end-to-end biotech developing transformational medicines, with technology at our core. Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure. Medicines born from high-resolution biology, machine learning and clinical insights. Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.
| Website | https://www.relationrx.com/ |
| Revenue | $5.3 million |
| Employees | 130 (95 on RocketReach) |
| Founded | 2019 |
| Industry | Biotechnology Research |
| Keywords | Biotechnology, Therapeutics, Drug Discovery, Pharmaceutical, Drug Development, Medicine Development, Biotech, Life Sciences, Disease Treatment, Pharmaceutical Research, Clinical Trials, Human Biology, Biomedical Research, Precision Medicine, New Drugs, Health Technology, Molecular Biology |
| Competitors | Merck AH, Bristol Myers Squibb, Amgen, Regeneron, Veeva Systems, Gilead Sciences, Vertex Pharmaceuticals, アステラス製薬(株), Lengo Therapeutics, Avillia Developments +46 more (view full list) |
Looking for a particular Relation Therapeutics employee's phone or email?
The Relation Therapeutics annual revenue was $5.3 million in 2026.
Benjamin Swerner is the COO and Co-founder of Relation Therapeutics.
95 people are employed at Relation Therapeutics.
Relation Therapeutics is based in London, England.